2026 Interim Results

AI SummaryClose X

Novacyt S.A. reported a 18% increase in unaudited statutory revenue to £11.6 million for the first half of 2026, with underlying organic growth around 9% excluding the impact of Southern Cross Diagnostics (SCD). The Instrumentation segment saw approximately 30% year-on-year revenue growth, while the Clinical segment grew over 20%, driven by the Reproductive Health range and SCD sales. The Group's gross margin decreased to 56% from 66% in the prior year, impacted by SCD sales and fair value adjustments. Operating expenses reduced to £10.3 million, and the EBITDA loss narrowed to £3.9 million. The company's cash position stood at £8.9 million as of June 30, 2026, with no debt. Significant operational highlights include the acquisition of SCD for £4.5 million and a Master Collaboration Agreement with Illumina.

Disclaimer*

UK 100

Latest directors dealings